DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA

Completed

Conditions studied: Psoriatic Arthritis

In brief

Biologics such as anti-Tumor Necrosis Factor or TNF inhibitor (TNFi) for treatment of Psoriatic Arthritis (PsA) has greatly reduced bone damage. This collaborative study will provide insights into key mechanisms that underlie inflammatory arthritis and bone damage in psoriatic joints and will catalyze biomarker discovery, identifying early biologic responders to facilitate optimization of therapy.

Key facts

Study ID

NCT02413749

Run by

University of Rochester

People needed

68

Starts

2015-04-13

Expected to finish

2016-12-28

Last updated by the study team

2017-08-18

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All Subjects
• Ability to provide written informed consent.
• Subjects can be of either gender but must be at least 18 years old.
• Subjects with PsA should fulfill CASPAR criteria
• Longitudinal
• Patients with active PsA starting standard of care biologic treatment.
• Additional Blood Draw
• Positive DC-STAMP signal at baseline
• Cross-Sectional 1. Patients on stable DMARDS or biologics for more than 16 weeks.

You may not qualify if…

• Unable to donate blood because of poor venous access or intolerance of phlebotomy.

Where it is running

• University of Rochester — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.